CRISPR Therapeutics

CRISPR Therapeutics

Biotechnology Research

Boston, MA 95,917 followers

Über uns

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom.

Website
http://www.crisprtx.com
Industrie
Biotechnology Research
Größe des Unternehmens
201-500 Mitarbeiter
Hauptsitz
Boston, MA
Typ
Öffentliches Unternehmen
Gegründet
2013
Spezialitäten
Gene Editing, AAV, Hematology, and Immuno-Oncology

Standorte

Employees at CRISPR Therapeutics

Aktualisierungen

Ähnliche Seiten

Jobs durchsuchen

Aktie

CRSP

NASDAQ

20 Minuten Verzögerung

$47.48

-0.76 (-1.576%)

Öffnen Sie
48
Niedrig
46.86
Hoch
48.435

Daten von Refinitiv

Siehe mehr Informationen auf Bing

Finanzierung

CRISPR Therapeutics 6 total rounds

Letzte Runde

Eigenkapital nach dem IPO

US$ 280.0M

Investoren

EcoR1 Capital
Siehe mehr Informationen auf crunchbase